| Afinitor (everolimus tablets) | Renal cell carcinoma | SUTENT (sunitinib) or NEXAVAR (sorafenib); prerequisite Part D drug required | Trial and failure, contraindication, or intolerance |
| Afinitor (everolimus tablets) | Advanced hormone receptor-positive, HER2-negative breast cancer | FEMARA (letrozole) or ARIMIDEX (anastrozole); prerequisite Part D drug required | Trial and failure, contraindication, or intolerance |
| Augtyro | Qualifying ROS1-positive NSCLC or NTRK fusion-positive solid tumor | Prerequisite Part D drug required | For NTRK tumors, disease must have progressed after prior treatment or have no satisfactory alternative treatment |
| Avmapki Fakzynja Co-pack | KRAS-mutated malignancy | Prerequisite Part D drug and prior systemic therapy required | Prior systemic therapy is required; continuation of prior therapy may be approved |
| Avtozma | Rheumatoid arthritis | Prerequisite Part D therapy; two listed agents or attestation that a trial may be inappropriate | Trial and failure, contraindication, or intolerance to two agents, unless continuing prior therapy |
| Avtozma | Polyarticular juvenile idiopathic arthritis | Prerequisite Part D therapy; two listed agents or attestation that a trial may be inappropriate | Trial and failure, contraindication, or intolerance to two agents, unless continuing prior therapy |
| Avtozma | Systemic juvenile idiopathic arthritis | Prerequisite Part D therapy; maximally tolerated NSAID trial | Minimum 1-month NSAID trial |
| Actimmune | Rheumatoid arthritis, giant cell arteritis, SJIA, PJIA, or SSc-ILD | Prerequisite Part D drug required | For RA/PJIA, applicable prior-agent requirements apply; for SJIA, a 1-month NSAID trial applies |
| Ayvakit | GIST, advanced systemic mastocytosis, or indolent systemic mastocytosis | No prerequisite Part D drug required | Disease-specific criteria apply; platelet count must be at least 50 × 10^9/L for systemic mastocytosis |
| Balversa | Locally advanced or metastatic urothelial carcinoma | Prerequisite Part D drug required; at least one prior systemic therapy | Disease progression after prior systemic therapy; prior PD-1/PD-L1 therapy or ineligibility required |
| Benlysta | SLE or lupus nephritis | No prerequisite Part D drug required | Must be receiving standard-of-care therapy; SLE requires ANA ≥1:80 or anti-dsDNA ≥30 IU/mL |
| Besremi | Polycythemia vera | Prerequisite Part D drug required | High-risk disease requires the stated prior-treatment trial; source criterion is incomplete |
| Bosulif | Philadelphia chromosome-positive CML | No prerequisite Part D drug required | Continuation of prior therapy may be approved |
| Braftovi | Melanoma or metastatic NSCLC | Prerequisite Part D drug required; use with Mektovi (binimetinib) | Required BRAF V600E/V600K mutation testing |
| Braftovi | Colorectal cancer | Prerequisite Part D drug required; use with Erbitux (cetuximab) | Prior therapy or fluorouracil-based chemotherapy required; BRAF V600E mutation required |
| Briviact | Partial-onset seizures | No prerequisite Part D drug required | Continuation of prior therapy may be approved |
| Brukinsa | Mantle cell lymphoma | Prerequisite Part D drug required | At least one prior therapy |
| Brukinsa | Marginal zone lymphoma | Prerequisite Part D drug required | Relapsed or refractory disease and at least one prior anti-CD20-based regimen |
| Brukinsa | Follicular lymphoma | Prerequisite Part D drug required; use with Gazyva | Relapsed or refractory disease and at least two prior systemic-therapy lines |
| Cabometyx | Hepatocellular carcinoma | Prerequisite Part D drug required; Nexavar | Trial and failure, contraindication, or intolerance to Nexavar |
| Cabometyx | Differentiated thyroid cancer | Prerequisite Part D drug required; prior VEGFR-targeted therapy | Progression after prior therapy and radioactive-iodine refractory or ineligible disease |
| Cabometyx | Pancreatic or extra-pancreatic neuroendocrine tumors | Prerequisite Part D drug required; previous treatment | Disease must be unresectable, locally advanced, or metastatic and well-differentiated |
| Calquence | Untreated mantle cell lymphoma | Prerequisite Part D drug required; bendamustine and rituximab combination | Autologous HSCT ineligibility required |
| Calquence | Previously treated mantle cell lymphoma | Prerequisite Part D drug required | At least one prior therapy |
| Caplyta | Schizophrenia | Prerequisite Part D drug required; two listed oral generic atypical antipsychotics | Trial and failure, contraindication, or intolerance to both agents |
| Caplyta | Bipolar depression | Prerequisite Part D drug required; quetiapine IR/ER or olanzapine | Trial and failure, contraindication, or intolerance |
| Caplyta | Adjunctive major depressive disorder | Prerequisite Part D drug required; aripiprazole and quetiapine IR/ER | Trial and failure, contraindication, or intolerance to both agents |
| Ciclopirox | Fingernail onychomycosis | Prerequisite Part D drug; oral terbinafine | Minimum 6-week supply with trial and failure, contraindication, or intolerance |
| Ciclopirox | Toenail onychomycosis | Prerequisite Part D drug; oral terbinafine | Minimum 12-week supply with trial and failure, contraindication, or intolerance |
| Cobenfy | Medically accepted indications | Prerequisite Part D drug; two oral generic formulary atypical antipsychotics | Intolerance to two agents: aripiprazole, asenapine, olanzapine, paliperidone, quetiapine IR/ER, risperidone, or ziprasidone |
| Copiktra | Relapsed or refractory CLL/SLL | Prerequisite Part D drug; at least two prior CLL/SLL therapies | Trial and failure, contraindication, or intolerance |
| Cosentyx | Plaque psoriasis | Prerequisite Part D drug; one topical therapy | Minimum 4-week trial and failure, contraindication, or intolerance |
| Cosentyx | Ankylosing spondylitis | Prerequisite Part D drug; one NSAID | Minimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated dose |
| Cosentyx | Non-radiographic axial spondyloarthritis or ERA | Prerequisite Part D drug; two NSAIDs | Minimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated doses |
| Actimmune | Plaque psoriasis | Prerequisite Part D drug; one topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor | Minimum 4-week trial with failure, contraindication, or intolerance |
| Actimmune | Ankylosing spondylitis | Prerequisite Part D drug; one NSAID | Minimum 1-month trial with failure, contraindication, or intolerance at maximally tolerated dose |
| Actimmune | Non-radiographic axial spondyloarthritis or ERA | Prerequisite Part D drug; two NSAIDs | Minimum 1-month trial with failure, contraindication, or intolerance |
| Cosentyx IV | Psoriatic arthritis | Two listed formulary therapies; prerequisite Part D drug required | Trial and failure, contraindication, or intolerance, unless continuing prior therapy |
| Cosentyx IV | Ankylosing spondylitis | Two listed formulary therapies; prerequisite Part D drug required | Trial and failure, contraindication, or intolerance, unless continuing prior therapy |
| Cosentyx IV | Non-radiographic axial spondyloarthritis | Cosentyx SC and Rinvoq; prerequisite Part D drug required | Trial and failure, contraindication, or intolerance to both, unless continuing prior therapy |
| Roflumilast | COPD | Prerequisite Part D drug; two prior COPD therapies | Trial and failure, intolerance, or contraindication to both |
| Metyrosine | Preoperative pheochromocytoma preparation | Prerequisite Part D drug; alpha-adrenergic blocker and beta-adrenergic blocker | Trial and failure, contraindication, or intolerance to both |
| Doptelet | Immune thrombocytopenia | Prerequisite Part D drug; corticosteroids, immunoglobulins, or splenectomy | Trial and failure, contraindication, or intolerance to at least one |
| Dulera | Asthma | Prerequisite Part D drug; Breo Ellipta | Intolerance to Breo Ellipta is referenced in the criteria |
| Dupixent | Applicable covered indication | Indication-specific prerequisite therapy; prerequisite Part D drug required | May include asthma controller, intranasal corticosteroid, topical therapy, COPD inhaler regimen, H1 antihistamine, or EoE therapy; contraindication or intolerance may apply |
| Ebglyss | Moderate to severe atopic dermatitis | Medium- or higher-potency topical corticosteroid or specified alternative; prerequisite Part D drug required | Minimum 30-day supply, or 14-day supply for topical corticosteroids; trial and failure, contraindication, or intolerance |
| Empaveli | C3G or primary IC-MPGN | ACE inhibitor, ARB, or SGLT2 inhibitor; prerequisite Part D drug required | Maximally tolerated therapy for at least 12 weeks before initiation and continued when required |
| Enbrel | Rheumatoid arthritis | Methotrexate, leflunomide, or sulfasalazine; prerequisite Part D drug required | Minimum 3-month trial and failure, contraindication, or intolerance |
| Enbrel | Polyarticular juvenile idiopathic arthritis | Leflunomide or methotrexate; prerequisite Part D drug required | Minimum 6-week trial and failure, contraindication, or intolerance |
| Enbrel | Plaque psoriasis | Topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor; prerequisite Part D drug required | 30-day supply, or 14-day supply for topical corticosteroids; failure, contraindication, or intolerance |
| Enbrel | Ankylosing spondylitis | One NSAID; prerequisite Part D drug required | Minimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated dose |
| Epidiolex | Lennox-Gastaut syndrome | Two formulary anticonvulsants; prerequisite Part D drug required | Trial, contraindication, or intolerance to both |
| Eucrisa | Mild to moderate atopic dermatitis | Prescription-strength topical corticosteroid; prerequisite Part D drug required | Trial and failure, contraindication, or intolerance, unless affected area is sensitive |
| Fasenra | Severe eosinophilic asthma | Age-appropriate ICS plus additional controller or qualifying ICS/LABA; prerequisite Part D drug required | Current therapy required unless contraindicated or intolerable |
| Fasenra | EGPA | Corticosteroid therapy; prerequisite Part D drug required | Current therapy required unless contraindicated or intolerable |
| Fasenra | HES | Corticosteroid or cytotoxic/immunosuppressive therapy; prerequisite Part D drug required | Failure, contraindication, or intolerance required |
| Fruzaqla | Metastatic colorectal cancer | Fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus anti-VEGF therapy; prerequisite Part D drug required | RAS-wild-type disease additionally requires anti-EGFR therapy plus Lonsurf or Stivarga |
| Humira | Rheumatoid arthritis | Methotrexate, leflunomide, or sulfasalazine | Minimum 3-month trial and failure, contraindication, or intolerance at maximally tolerated doses |
| Humira | Polyarticular juvenile idiopathic arthritis | Leflunomide or methotrexate | Minimum 6-week trial and failure, contraindication, or intolerance at maximally tolerated doses |
| Humira | Plaque psoriasis | Topical corticosteroid, vitamin D analog, tazarotene, or calcineurin inhibitor | 30-day supply, or 14-day supply for topical corticosteroids; failure, contraindication, or intolerance |
| Humira | Ankylosing spondylitis | One NSAID | Minimum 1-month trial and failure, contraindication, or intolerance at maximally tolerated dose |
| Hyrnuo | Locally advanced or metastatic HER2-mutated non-squamous NSCLC | Prior systemic therapy such as chemotherapy; prerequisite Part D drug required | Prior systemic therapy must be documented |
| Igalmi | Acute agitation associated with schizophrenia or bipolar I/II disorder | At least two acute-agitation products; prerequisite Part D drug required | Trial and failure, contraindication, or intolerance to at least two products |
| Imbruvica | Chronic graft-versus-host disease | Prior systemic therapy; prerequisite Part D drug required | Trial and failure of one or more lines of systemic therapy |
| Inbrija | Parkinson disease with intermittent OFF episodes | Two of: MAO-B inhibitor, dopamine agonist, or COMT inhibitor; prerequisite Part D drug required | Trial and failure, contraindication, or intolerance to two classes |
| Inflectra | Plaque psoriasis | One qualifying topical therapy; prerequisite Part D drug required | Minimum 4-week trial and failure, contraindication, or intolerance |
| Inflectra | Crohn disease, fistulizing Crohn disease, or ulcerative colitis | One qualifying conventional therapy; prerequisite Part D drug required | Trial and failure, contraindication, or intolerance |